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Abstract
Background: A common sequence polymorphism at codon 72 of the p53 gene encoding either
arginine or proline was recently shown to be functionally relevant for apoptosis induction in vitro.
In B-type chronic lymphocytic leukemia (B-CLL), p53 gene mutations occur in a subset of patients
and are associated with impaired survival and drug resistance. Here, we address the functional
relevance of the codon 72 single nucleotide (SNP) polymorphism for cell death sensitivity following
exposure to clinically employed cytotoxic drugs and γ-irradiation.
Methods: 138 B-CLL samples were analysed by SSCP-PCR and sequencing for single nucleotide
polymorphism at codon 72 of the p53 gene. The in vitro cytotoxicity assay (DiSC-assay) was
performed with 7 drugs (chlorambucil, mafosfamide, fludarabine phosphate, methylprednisolone,
doxorubicin, vincristine) or γ-irradiation.
Results: Of the138 B-CLL samples, 9 samples were homozygous for proline (Pro/Pro), 78 samples
homozygous for arginine (Arg/Arg), and 49 samples heterozygous (Arg/Pro). No differences were
found for patient survival and cell death triggered by 7 cytotoxic drugs or γ-irradiation.
Conclusion: These data indicate that polymorphic variants of p53 codon 72 are not clinically
relevant for apoptosis induction or patient survival in B-CLL.
Background
The tumor suppressor gene p53 plays a central role in the
induction of cell cycle arrest, senescence and apoptosis [1-
5]. The polyproline domain (PP domain) of p53 spanning
amino acids 62–91 is involved in apoptosis induction and
facilitates transactivation of pro-apoptotic genes by p53
[6].
Located in this PP domain is at codon 72 a common sin-
gle nucleotide polymorphism (SNP), resulting in either a
proline residue (p53Pro) or an arginine residue (p53Arg).
Thus, each individual inherits a p53 genotype that can be
heterozygous (Arg/Pro) or homozygous for either
arginine (Arg/Arg) or proline (Pro/Pro). The polymor-
phism is balanced, varies with latitude and race, and is
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maintained at different allelic frequencies across the pop-
ulation [7]. These two SNPs appear to be different both
biochemically and biologically [8-11]. Differences in
apoptosis susceptibility to cytotoxic drugs were described
[12,13], and the response and survival to radiochemo-
therapy in clinical samples of squamous cell carcinomas
was found to be increased in case the arginine allele is
retained [13].
Chronic lymphocytic B-cell lymphoma is still an incura-
ble disease and may be addressed as a disease of intrinsic
apoptosis deficiency. It is a disease where the mutational
status of the p53 gene is linked to patient survival [14]
(and references herein). We therefore asked whether the
codon 72 polymorphism is of clinical relevance for in
vitro resistance to cytotoxic drugs, γ-irradiation and
patient prognosis.
Methods
Patients
Samples from 138 B-CLL patients (99 male, 39 female,
age 63.2 ± 0.5 (mean ± SEM) were analysed. Peripheral
blood was analysed for drug sensitivities using fresh cells.
The same samples were analysed for mutations in the p53
DNA binding domain and of the p53 codon 72 SNP,
using snap frozen cells from the same specimens. Only
patients with high peripheral blood leukocyte count were
included in this analysis (median WBC 120.8/nl, range
20.7–1262.2/nl). The Binet stage was A in 29 cases, B in
24 cases, A/B in 15 cases (due to insufficient information
on clinical lymph node status) and C in 62. Of the 138
patients, 80 were pretreated (58%) with one to six drug
regimens (mean number of pretreatments for these 80
patients ± SEM: 1.93 ± 1.005). Median survival was 30.1
months; median follow up for the 17 censored patients
was 97.9 months. This study was performed in accordance
with local ethical standards and the declaration of
Helsinki.
Analysis of p53 codon 72 polymorphism
SNP in the p53 codon 72 were analysed by genomic SSCP-
PCR analysis and DNA sequencing. The primers were
CGG ACG ATA TTG AAC AAT GG (sense) and CGT TTT
CTG GGA AGG GAG AG (antisense), resulting in a PCR
product of 167 bp. A standard PCR reaction in 50 µl with
a final concentration of 0.6 mM MgCl2 was performed (40
cycles, annealing temperature 56°C). PCR products were
denatured and separated on a nondenaturating 10% poly-
acrylamide gel at 500 V and 50 mA for 2 h at 22°C and
analysed by silver staining [15,16]. Sequence polymor-
phism was confirmed by DNA sequencing, as described
[14]. A result was obtained in 136 samples (98.6%).
Mutations in the DNA-binding domain of the p53 gene
(exon 5 to 8) has been analyzed previously by the use of
SSCP-PCR and sequencing as described in detail else-
where [14].
Chemosensitivity assay
B-CLL cells were exposed to cytotoxic drugs (chloram-
bucil, mafosfamide, fludarabine phosphate, methylpred-
nisolone, doxorubicin, vincristine) or γ-irradiation (2 Gy)
and cultured for 92 h. Percentages of drug-induced cell
death and LD90 doses were determined by the use of a
standardized morphometric test, the DiSC assay [17,18].
Data analysis
For intervariable assessment, the non-parametric Mann-
Whitney U-test (for 2 groups) or the Kruskal-Wallis test
(for 3 groups) or the χ2-test or Fisher's exact test for cate-
gorical parameters were applied. Overall survival was esti-
mated by the Kaplan-Meier product-limit method. For the
chemosensitivity data, LC90 doses were determined by cal-
culating the log dose at which the fitted survival probabil-
ity was equal to 0.1. LC90 values were logged (base 10)
before calculation of mean and SEM, as described [19].
Results
Codon 72 SNP and clinical data
Of the 138 samples analysed, 136 could be amplified by
genomic PCR : 78 samples were Arg/Arg, 9 samples were
Pro/Pro, and 49 samples were Arg/Pro. Patients age and
gender was not different in the subgroups (63.3 ± 1.07
years; male/female 55/23 in Arg/Arg, 65.2 ± 2.7 years,
Analysis of p53 codon 72 SNP in B-CLL Figure 1
Analysis of p53 codon 72 SNP in B-CLL. Silver-stained 
polyacrylamide gel of 6 B-CLL samples analysed by SSCP-
PCR for the codon 72 SNP. Sequencing of the 138 B-CLL 
samples confirmed the polymorphisms in p53 gene, codon 72 
(exon 4): 6.6% of the samples were homozygous for proline 
(Pro/Pro), 57.4% were homozygous for arginine (Arg/Arg), 
and 36% were heterozygous with both an arginine and a pro-
line allele (Arg/Pro).BMC Cancer 2005, 5:105 http://www.biomedcentral.com/1471-2407/5/105
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male/female 6/3 in Pro/Pro, 63.2 ± 1.5; male/female 37/
12 in Pro/Arg). In the Binet's stage, the distribution was:
stage A: 18 Arg/Arg, 1 Pro/Pro, 10 Pro/Arg; stage B: 10 Arg/
Arg, 1 Pro/Pro, 13 Pro/Arg; stage C: 37 Arg/Arg, 6 Pro/Pro,
18 Pro/Arg; stage A or B: 9 Arg/Arg, 1 Pro/Pro, 5 Pro/Arg
(p = 0.6).
78 patients were pretreated with a median of 2 treatment
regimens. There was, however, no association between
pretreatment status and codon 72 SNP (p = 0.6).
Codon 72 SNP and IgVH and p53 gene mutational analysis
In 113 samples, the IgVH-gene status was known, and in
all 136 cases the p53 genotype was known [14]. Concern-
ing the IgVH-gene status, of the hypermutated samples, 19
were Arg/Arg, 0 Pro/Pro, 10 Pro/Arg and of the pre-germi-
nal center samples, 50 were Arg/Arg, 6 Pro/Pro, 28 Pro/
Arg (p = 0.3). Concerning the p53 genotype of the B-CLL
samples, of the 22 p53-mutated samples, 17 were Arg/Arg,
2 Pro/Pro, 3 Pro/Arg and of the 114 p53-wildtype sam-
ples, 61 were Arg/Arg, 7 Pro/Pro, 46 Pro/Arg (p = 0.06).
Codon 72 SNP and survival
There was no difference in overall survival for the 3 differ-
ent groups (p = 0.885) (Fig. 1B). This was also true when
only the p53 wild type samples were analysed (p = 0.46).
Codon 72 SNP and cell death sensitivity
For none of the tested drugs (chlorambucil, mafosfamide,
doxorubicine, vincristine, fludarabine, caldribine and
methylprednisolone), a correlation to the p53 codon 72
SNP was seen. This was the case irrespective of the p53
mutational status (Table 1). For γ-irradiation, there was a
trend (p = 0.099) for better survival of the B-CLL cells
when the sample is homozygous for proline. This finding
is in accordance with a recent report on response rates and
survival of head and neck carcinoma patients treated with
radiochemotherapy where patients with a homozygous
proline genotype had an impaired outcome to treatment
[13]. This association of the Pro/Pro genotype failed, how-
ever, to attain statistical significance. This, together with
the lack of correlation with patient survival indicates a
rather limited clinical relevance of such codon 72
polymorphisms.
Discussion
Recently, a sequence polymorphism at codon 72 the p53
gene (exon 4) encoding either arginine (CGC) or proline
(CCC) was suggested to result in a drastically altered bio-
logical and biochemical behaviour of p53 in vitro. Com-
pared to the proline encoding allele, the arginine allele
appeared to trigger a more pronounced apoptosis
response, whereas the proline allele induced significantly
more G1 arrest [8,10,13].
The question of clinical relevance was addressed in a few
case control studies. There, the proline allele was associ-
ated with urothelial [20], thyroid [21,22], and colorectal
carcinomas [23] and chronic myeloid leukemia [24],
whereas homozygosity for arginine was associated with
Table 1: Resistance to ionising irradiation and cytotoxic drugs in relation to the p53 codon 72 status
all patients p53 wild type
p53 codon 
72 Arg/Arg
p53 codon 
72 Pro/Pro
p53 codon 
72 Arg/Pro
p p53 codon 
72 Arg/Arg
p53 codon 
72 Pro/Pro
p53 codon 
72 Arg/Pro
p
γ-irradiation
(% surviving cells)
36.3 ± 4.7
(n = 49)
50.0 ± 10.1
(n = 7)
24.2 ± 4.8
(n = 26)
0.099 30.6 ± 4.8
(n = 39)
54.7 ± 13.4
(n = 5)
22.9 ± 4.9
(n = 25)
0.14
log10 LC90 chlorambucil 0.73 ± 0.07
(n = 78)
0.76 ± 0.19
(n = 9)
0.62 ± 0.08
(n = 49)
0.63 0.6 ± 0.08
(n = 61)
0.76 ± 0.22
(n = 7)
0.57 ± 0.08
(n = 46)
0.70
log10 LC90 mafosfamide 0.32 ± 0.05
(n = 75)
0.37 ± 0.12
(n = 9)
0.21 ± 0.05
(n = 47)
0.39 0.3 ± 0.06
(n = 59)
0.38 ± 0.16
(n = 7)
0.21 ± 0.05
(n = 44)
0.42
log10 LC90 fludarabine 0.18 ± 0.08
(n = 78)
0.13 ± 0.18
(n = 9)
-0.32 ± 0.1
(n = 49)
0.32 0.11 ± 0.1
(n = 61)
0.22 ± 0.23
(n = 7)
-0.06 ± 0.01
(n = 46)
0.28
log10 LC90 cladribine -0.76 ± 0.1
(n = 78)
-0.85 ± 0.18
(n = 9)
-1.0 ± 0.11
(n = 49)
0.10 -0.89 ± 0.1
(n = 61)
-0.79 ± 0.22
(n = 7)
-1.04 ± 0.11
(n = 46)
0.22
log10 LC90 vincristine 0.13 ± 0.1
(n = 55)
0.01 ± 0.27
(n = 8)
-0.22 ± 0.11
(n = 39)
0.71 -0.14 ± 0.11
(n = 40)
0.05 ± 0.33
(n = 6)
-0.25 ± 0.11
(n = 36)
0.59
log10 LC90 doxorubicin -0.55 ± 0.04
(n = 78)
-0.52 ± 0.06
(n = 9)
-0.61 ± 0.05
(n = 49)
0.64 -0.55 ± 0.05
(n = 61)
-0.49 ± 0.07
(n = 7)
-0.63 ± 0.05
(n = 46)
0.35
log10 LC90 methylprednisolone 0.99 ± 0.14
(n = 78)
1.36 ± 0.45
(n = 9)
0.95 ± 0.18
(n = 48)
0.70 0.99 ± 0.16
(n = 61)
1.52 ± 0.47
(n = 7)
0.95 ± 0.18
(n = 45)
0.57
For the cytostatic drugs (chlorambucil, mafosfamide, fludarabine, cladribine, vincristine, doxorubicin or methylprednisolone) log10 LC90 
concentrations were compared. In case of ionizing γ-irradiation with a fixed dose of 2 Gy, percentages of surviving cells were compared. p53 WT: 
wild type p53 gene. Mean +/- SEM is given. Statistical significance was calculated by means of the Kruskal-Wallis test.BMC Cancer 2005, 5:105 http://www.biomedcentral.com/1471-2407/5/105
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advanced lung cancer [25]. Concerning patient outcome,
in Italian breast cancer patients, the retention of an
arginine allele was correlated with a reduction of survival
in one study [26]. Another study addressed the clinical rel-
evance of this SNP for treatment response in solid tumors.
There, the homozygous proline genotype was correlated
with impaired response to radiochemotherapy and
reduced survival in head and neck carcinoma [13]. Fur-
thermore, p53 protein encoded by the arginine allele
appears to be more susceptible to HPV-E6 protein-
induced degradation [27]. Although many studies investi-
gated the relationship of the allelic distribution and sus-
ceptibility to HPV-associated cervical carcinoma, two
recent meta-analyses could not establish such a correla-
tion with the p53 gene codon 72 SNP [28,29].
In B-CLL, the p53 gene is known to be of clinical relevance
concerning survival and treatment response [14]. We
therefore investigated the potential clinical relevance of
the p53 gene codon 72 SNP in a cohort of 138 samples
from patients with B-CLL with respect to survival and drug
sensitivity.
The distribution of the proline and arginine alleles in the
B-CLL samples was, however, not different of frequency
distributions observed in the general population [7].
Moreover, we found no correlation between codon 72
p53 SNP and p53 Exon 5–8 mutations or the IgVH hyper-
mutation status or clinical Binet stage. Likewise, survival
was not different in the p53 codon 72 SNP subgroups.
Furthermore, no correlation with in vitro drug sensitivities
was seen. The trend for reduced sensitivity to irradiation
in case of homozygosity for proline is in accordance with
a previous report in head and neck cancer [7], but fails to
reach statistical significance. These data indicate that the
codon 72 SNPs of p53 have per se no clinical relevance, at
least in B-CLL. This may indicate either that B-CLL differs
significantly from other tumors with regard to the regula-
tion of cell death induced by cytotoxic anticancer thera-
pies or that positive reports from other studies in clinical
samples are false positive, eg. due to small sample size.
Conclusion
Although p53 gene mutations in the DNA-binding
domain are clinically relevant for patients with B-CLL, the
p53 gene codon 72 SNP was not found to be of clinical
relevance in patients with B-CLL, neither for patient sur-
vival nor for ex vivo sensitivity for cytotoxic drugs and γ-
irradiation.
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